


Bimoclomol

Cat. No.:	HY-U00398
CAS No.:	130493-03-7
Molecular Formula:	C ₁₄ H ₂₀ ClN ₃ O ₂
Molecular Weight:	297.78
Target:	HSP
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (335.82 mM; Need ultrasonic)				
	Preparing Stock Solutions	<div>Solvent Concentration</div> <div>Mass</div>	1 mg	5 mg	10 mg
		1 mM	3.3582 mL	16.7909 mL	33.5818 mL
		5 mM	0.6716 mL	3.3582 mL	6.7164 mL
		10 mM	0.3358 mL	1.6791 mL	3.3582 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (8.40 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.40 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Bimoclomol is a heat shock protein (HSP) coinducer, used for treatment of cardiovascular diseases.
IC ₅₀ & Target	HSP
In Vitro	Bimoclomol (40 μM) significantly increases coronary flow (CF) in the period of normoxic perfusion (before ischemia). Bimoclomol significantly increases LVDP and CO, but it decreases LVEDP under ischemic conditions. Bimoclomol displays a biphasic effect on the rate of relaxation. Bimoclomol (>10 μM) causes concentration-dependent vasorelaxation, with EC ₅₀ value of 214 μM. Bimoclomol (100 μM) induces vasorelaxation also against 20 mM KCl. However, bimoclomol fails to relax preparations precontracted with serotonin, PGF ₂ or angiotensin II ^[1] . Bimoclomol does not affect the stability of Hsp70 or its mRNA. Bimoclomol coinduces Hsp expression via the prolonged activation of the heat shock transcription factor (HSF-1). The effects of bimoclomol are abolished in cells from mice lacking HSF-1. Furthermore, bimoclomol can bind to HSF-1 and

induce a prolonged binding of HSF-1 to the respective DNA elements^[2]. Bimoclolmol (0.1, 1 and 10 μ M) improves cell survival of rat neonatal cardiomyocytes compared to vehicle-treated cells. Bimoclolmol (0.01 to 10 μ M) significantly elevates HSP70 levels, based on the time of exposure. Pretreatment with bimoclolmol for 24 h significantly increases survival of cells^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Bimoclolmol (1 and 5 mg/kg) decreases the ST-segment elevation induced by coronary occlusion by 56% and 80%, respectively, in anesthetized dogs^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[3]

Using the same cell preparation, a cytoprotection (cell survival) assay is configured to assess the ability of bimoclolmol to protect cells exposed to a lethal stress. To optimize the cell survival determinations, final plating densities for this protocol are reduced to approximately 0.5 million cells/mL. Plated cardiomyocytes are placed in an incubator (37°C, 5% CO₂) for 24 h. The plates are removed from the incubator and the media changed to serum free. Separate sets of cells are either heat shocked at 42°C for 1 h or treated as sham (no heat shock). Bimoclolmol is then added to individual wells at 0, 0.01, 0.1, 1, 10 and 100 μ M and the plates are placed back in the 37°C incubator for 24 h. The plates are removed from the incubator and after another media change, (serum free) all plates are exposed to a lethal heat stress for 2 h in a waterbath set at 47°C. The plates are then placed back in the 37°C incubator overnight (16-18 h). The following morning, cell survival is determined using trypan blue exclusion. Equal volumes of culture medium and trypan blue solution are mixed. After removing the spent media from the wells, the above mixture is added to the wells for 10 min. The cells are then washed three times with cold PBS and counted with an inverted light microscope (10 \times). The final survival values from this protocol are expressed as the percentage of viable cells per treatment using the formula [(stained cells–total cells)÷total cells]×100. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Jednakovits A, et al. In vivo and in vitro acute cardiovascular effects of bimoclolmol. *Gen Pharmacol*. 2000 May;34(5):363-9.
- [2]. Hargitai J, et al. Bimoclolmol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. *Biochem Biophys Res Commun*. 2003 Aug 1;307(3):689-95.
- [3]. Polakowski JS, et al. Bimoclolmol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. *Eur J Pharmacol*. 2002 Jan 18;435(1):73-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA